Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

48.54 +0.27 (+0.56%)
Streaming Delayed Price Updated: 3:32 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 226,331
Open 48.43
Bid (Size) 48.40 (4)
Ask (Size) 48.54 (1)
Prev. Close 48.27
Today's Range 47.21 - 49.28
52wk Range 21.06 - 66.47
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
Exposures COVID-19
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
From Prothena Corporation plc
Via Business Wire

Performance

YTD
-9.27%
-9.27%
1 Month
-9.14%
-9.14%
3 Month
-14.15%
-14.15%
6 Month
+59.88%
+59.88%
1 Year
+28.89%
+28.89%

More News

Read More
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Earnings Outlook For Prothena Corp
Via Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Analyst Expectations for Prothena Corp's Future
Via Benzinga
Earnings Scheduled For February 23, 2023
Via Benzinga
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know
Via Benzinga
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
Via Talk Markets
How To Weather These Choppy Markets
Via Talk Markets
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
Via Talk Markets
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Why Prothena Shares Are Trading Lower
Via Benzinga
Why Prothena Shares Are Nosediving During Tuesday's After-Hours Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Proposed Public Offering of Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.